[RET Fusion-Positive Solid Tumor].

Selpercatinib, a RET inhibitor, is covered by insurance for all solid tumors that are positive for the RET fusion gene. The RET fusion gene is positive in 2% of lung cancers and 10-20% of papillary thyroid cancers. In other solid tumors, positivity is less than 0.5%. However, if positive, treatment is expected to be effective, so it is desirable to actively perform cancer gene panel testing.